NNVC: financial statements from SEC — TradeAlmanac

NNVC

NanoViricides, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024
Research and development	1m	1m	993,066	1m	1m	2m
Selling, general and administrative	744,276	1m	803,619	966,905	902,700	1m
Operating expenses	2m	2m	2m	2m	2m	3m
Operating income	−2m	−2m	−2m	−2m	−2m	−3m
Net income	−2m	−2m	−2m	−2m	−2m	−3m
Earnings per share	−0.09	−0.11	−0.10	−0.14	−0.14	−0.23
Earnings per share, diluted	−0.09	−0.11	−0.10	−0.14	−0.14	−0.23
Weighted average shares	22m	20m	17m	16m	15m	14m
Weighted average shares, diluted	22m	20m	17m	16m	15m	14m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	3m	5m	1m	2m	3m	4m	4m	5m
Current assets	3m	5m	1m

Cash flow

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024
Operating cash flow	—	—	−2m	—	—	−3m
Depreciation and amortisation	127,566	131,016	130,752	189,114

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)